This hypothesis proposes that CD38, the primary NAD+-consuming enzyme, represents a more effective therapeutic target than NAD+ precursor supplementation for preventing poly(ADP-ribose) polymerase (PARP1)-driven metabolic catastrophe. CD38 accounts for approximately 80-90% of cellular NAD+ consumption through its NADase and ADP-ribosyl cyclase activities, creating a metabolic bottleneck that limits NAD+ availability for essential processes including SIRT1/3-mediated mitochondrial biogenesis and PARP1-dependent DNA repair. During conditions of oxidative stress or DNA damage, PARP1 hyperactivation rapidly depletes cellular NAD+ pools, triggering a cascade of metabolic dysfunction including impaired glycolysis, compromised mitochondrial respiration, and reduced SIRT1/3 activity. Rather than attempting to replenish NAD+ through precursor supplementation, which may be inefficient due to continued CD38-mediated degradation, selective CD38 inhibition using compounds such as 78c or apigenin would preserve endogenous NAD+ pools more effectively.

This hypothesis proposes that CD38, the primary NAD+-consuming enzyme, represents a more effective therapeutic target than NAD+ precursor supplementation for preventing poly(ADP-ribose) polymerase (PARP1)-driven metabolic catastrophe. CD38 accounts for approximately 80-90% of cellular NAD+ consumption through its NADase and ADP-ribosyl cyclase activities, creating a metabolic bottleneck that limits NAD+ availability for essential processes including SIRT1/3-mediated mitochondrial biogenesis and PARP1-dependent DNA repair. During conditions of oxidative stress or DNA damage, PARP1 hyperactivation rapidly depletes cellular NAD+ pools, triggering a cascade of metabolic dysfunction including impaired glycolysis, compromised mitochondrial respiration, and reduced SIRT1/3 activity. Rather than attempting to replenish NAD+ through precursor supplementation, which may be inefficient due to continued CD38-mediated degradation, selective CD38 inhibition using compounds such as 78c or apigenin would preserve endogenous NAD+ pools more effectively. This approach would maintain higher baseline NAD+ levels, ensuring adequate substrate availability for both constitutive SIRT1/3 activity and emergency PARP1 activation without triggering metabolic crisis. The hypothesis predicts that CD38 inhibition will demonstrate superior metabolomic profiles compared to NAD+ precursor supplementation, particularly in maintaining ATP/ADP ratios, preserving TCA cycle intermediates, and sustaining amino acid metabolism during oxidative challenge. This intervention would be particularly relevant in age-related metabolic disorders, neurodegenerative diseases, and ischemia-reperfusion injury where CD38 expression is elevated and NAD+ depletion contributes to pathogenesis.